FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

FibroGen (NASDAQ: FGEN) will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York.

Rhea-AI Summary

FibroGen (NASDAQ: FGEN) will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York. Thane Wettig, Chief Executive Officer, will participate in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts" on December 11 at 12:15 PM ET at the Sofitel New York. FibroGen management will be available for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.

Argus Dec 3 session

+0.50% close to close Open Argus

Details

News Market Reaction – FGEN

In the Dec 3 session, FGEN gained 0.50%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FibroGen’s participation in the Oppenheimer Movers in Rare Disease Summ...

Analysis

This announcement highlights FibroGen’s participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, including a panel focused on near‑term, potentially stock‑moving catalysts and one‑on‑one investor meetings. In context of recent balance sheet strengthening and clinical progress, the event underscores management’s focus on investor outreach. Key items to watch are any new disclosures around upcoming catalysts, clinical timelines, or strategic updates discussed during the conference.

Key Figures

Conference date: December 11, 2025 Panel time: 12:15 PM ET

Conference date

December 11, 2025

Oppenheimer Movers in Rare Disease Summit in New York

Panel time

12:15 PM ET

Elevator Pitches from Rare Disease Companies panel on December 11, 2025

Historical Context

5 past events · Latest: Dec 02

5 events

1. Dec 02

   Conference appearance

   24h Move

   +0.5%

   Announcement of Oppenheimer rare disease summit presentation and 1x1 investor meetings.

2. Nov 10

   Earnings and update

   24h Move

   -0.3%

   Q3 2025 results, China sale proceeds, cash runway into 2028, clinical updates.

3. Nov 03

   Earnings scheduling

   24h Move

   -0.1%

   Announcement of Q3 2025 earnings date and webcast details for investors.

4. Sep 24

   Clinical trial start

   24h Move

   +3.4%

   Initiation of Phase 2 monotherapy trial of FG‑3246 in mCRPC patients.

5. Sep 02

   Asset divestiture

   24h Move

   +3.0%

   Completion of FibroGen China sale to AstraZeneca and extension of cash runway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY.

Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York.

FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. 

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will FibroGen (FGEN) present at the Oppenheimer Rare Disease Summit?

FibroGen will present on December 11, 2025 at the Sofitel New York during the Oppenheimer Movers in Rare Disease Summit.

What time is Thane Wettig speaking for FibroGen (FGEN) on December 11, 2025?

Thane Wettig will speak on the panel at 12:15 PM ET on December 11, 2025.

What panel will FibroGen (FGEN) participate in at the Oppenheimer summit?

FibroGen will join the panel titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts".

How can investors schedule one-on-one meetings with FibroGen (FGEN) management at the conference?

Interested investors should contact their Oppenheimer representative to request or schedule one-on-one meetings with FibroGen management.

Will FibroGen (FGEN) make presentation materials or a webcast available from the December 11, 2025 event?

The announcement states management will present and meet attendees; contact the company or Oppenheimer representative for availability of materials or webcasts.

Who is the FibroGen (FGEN) executive speaking at the Oppenheimer Movers in Rare Disease Summit?

Thane Wettig, Chief Executive Officer of FibroGen, will participate in the panel on December 11, 2025.